China
Africa
Explore chapters and articles related to this topic
Drugs and Therapeutics
Published in James Sherifi, General Practice Under the NHS, 2023
Doctors could dispense from either an on-site dispensary or a standalone pharmacy. More rigorous regulations covered the latter than the former. Creating an on-site commercial pharmacy was time-consuming, expensive, and potentially controversial.45 The practice had to provide evidence to the CCG, supporting the claim that a proportion of its patient population resided more than 1.0 miles from the nearest high street chemist. Patients within that radius retained the right to have their prescription dispensed at the surgery or any pharmacy. Few chose to do go elsewhere, since the convenience of a one-stop shop, consultation and medication, outweighed choice. The on-site pharmacy had to be registered as a business independent of the GP partnership. Any conflict of interest had to be avoided.46 A qualified pharmacist had to be in charge. Rent had to be paid to the practice if the pharmacy was sited in the practice building. All business accounts had to be separate from those of the practice.
Legal Landscape
Published in Betty Wedman-St Louis, Cannabis as Medicine, 2019
However, despite common logic suggesting it best to rely upon recommendations from medical professionals, the available research on medical marijuana for physicians, and there familiarity with medical marijuana, is even lacking. As a result, without the benefit of definitive research, patients may enter a dispensary and often rely on the advice of “budtenders”—salespeople at dispensaries—in selecting specific strains or product types of medical marijuana in order to treat certain medical and disease conditions. Generally, states prohibit budtenders from providing medical advice to patients as budtenders lack the medical expertise legally required to provide any medical advice; however, such a scenario should not be surprising given the budtenders may possess the greatest familiarity with the available products types.
Clinical recommendations and dosing guidelines for cannabis
Published in Betty Wedman-St. Louis, Cannabis, 2018
Medical personnel ordering cannabis products need to meet state requirements and ensure that the patient meets eligibility criteria for using cannabis. First-time patients arriving at a dispensary need assistance for registration, purchasing, and selecting products [1]. Discussion with the patient helps define what cannabis product(s) may be correct for them. A chemotherapy patient's needs will differ greatly from a Parkinson's disease sufferer or a diabetic with neuropathy [2].
Comparing older nonmedical and medical cannabis users: health-related characteristics, cannabis use patterns, and cannabis sources
Published in The American Journal of Drug and Alcohol Abuse, 2021
Namkee G. Choi, Diana M. DiNitto
Results on sources used to obtain cannabis are the first to be reported among older cannabis users and show differences between nonmedical and medical users. One fifth of medical users bought their cannabis at a medical cannabis dispensary, but more than half bought it from other sources evenly divided between private/informal venues and commercial venues, possibly including nonmedical/recreational cannabis dispensaries. Findings that a quarter of medical users and slightly less than half of nonmedical users did not buy their last cannabis but obtained it mostly as gifts or through trading suggests that cannabis is readily available and accessible to older cannabis users for medical or nonmedical purposes. In fact, 86% of nonmedical users and 95% of medical users reported obtaining cannabis to be fairly or very easy.
Medical Cannabis Use: Exploring the Perceptions and Experiences of Older Adults with Chronic Conditions
Published in Clinical Gerontologist, 2021
Lydia Manning, Lauren Bouchard
In 2013, Illinois passed the Compassionate use of Medical Cannabis Pilot Program and patients with a qualifying condition and a medical cannabis card issued by the Illinois Department of Public Health were permitted to begin purchasing medical cannabis at a local and approved dispensary beginning in January, 2016. Despite cannabis’s federal status as a Schedule I drug, Illinoisans could access medical cannabis after applying in conjunction with a physician. This “pilot” status of the program has now been removed and several more qualifying conditions have been added. The state also implemented specific protocol for a short-term opioid alternative option, which is valid for 90 days in lieu of opioid medications after accidents, surgeries, or acute health events, which may also disproportionately affect older people. In January of 2020, Illinois also legalized recreational cannabis for the general population.
Exploring New Use of Cannabis among Older Adults
Published in Clinical Gerontologist, 2021
Jennifer Baumbusch, Isabel Sloan Yip
Canada is the second nation to legalize recreational, or non-medical, cannabis (Mahamad & Hammond, 2019). The landscape of the cannabis industry can be complex for new users to navigate. Essentially, there are two main categories of cannabis: medical and recreational. Access to medical cannabis is authorized by a healthcare provider, that is, physicians and nurse practitioners (Balneaves, Alraja, Ziemianski, McCuaig, & Ware, 2018; Valleriani, 2020). Once an individual receives authorization, they can obtain medical cannabis from a licensed producer, register to grow it themselves, or designate a person to produce their cannabis (Health Canada, 2020). Recreational cannabis does not require authorization and is used for a variety of reasons, including medicinal use. For example, in a 2017 Canadian survey about cannabis use, 12 percent of respondents reported using cannabis for medicinal purposes, however, the majority (71 percent) did not have authorization for this purpose (Statistics Canada, 2017). There are two main categories of retailers for recreational cannabis: licensed and non-licensed. A licensed retailer is described as “a regulated retailer or licensed dispensary; regulated by each province and territory, as government-operated, privately licensed stores, or online” (Kamrul, Bunka, Crawley, Schuster, & Lebras, 2019, p. 807). Within this growing industry, and in the absence of appropriate regulation, there is potential for cannabis to marketed toward consumers for medicinal or “wellness” purposes without sufficient empirical evidence to support these claims (Hall, 2018).